Becatecarin
- Generic Name
- Becatecarin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C33H34Cl2N4O7
- CAS Number
- 119673-08-4
- Unique Ingredient Identifier
- A60X6MBU6G
- Background
Becatecarin is a derivative of rebeccamycin.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 248
- Registration Number
- NCT00090025
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇮🇹Policlinico Universitario di Udine, Udine, Italy
🇨🇦Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00087204
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00086983
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00084487
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00006262
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00005085
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Atlanta Cancer Care, Atlanta, Georgia, United States
🇺🇸Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
- Conditions
- First Posted Date
- 2003-08-08
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00005027
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00004189
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸St. Luke's Lutheran Hospital, San Antonio, Texas, United States
Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003737
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 200
- Registration Number
- NCT00006102
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia, United States
🇺🇸Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.